---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-019405"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:13:55.052753+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q4 revenue $47.7M, GAAP net loss $2.3M; FY adj EBITDA $138M, guides FY26 >$300M

## Summary
- Full-year 2025 total revenue $296M, GAAP net income $24M ($0.15 diluted EPS), adjusted EBITDA $138M.
- Q4 2025 total revenue $47.7M (down 47% YoY); GAAP net loss $2.3M vs net income $2.3M in Q4 2024.
- LINZESS EUTRx demand grew 11% YoY in FY2025; over 5.7M unique patients treated since launch.
- Provides FY2026 guidance: LINZESS U.S. net sales $1.125-1.175B, total revenue $450-475M, adj EBITDA >$300M.
- Apraglutide confirmatory Phase 3 trial (STARS-2) design finalized; site initiations expected Q2 2026.

## SEC filing metadata
- accession: 0001104659-26-019405
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465926019405/0001104659-26-019405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465926019405/tm267094d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-019405
- JSON: https://secwatch.observer/filing/0001104659-26-019405.json
- Plain text: https://secwatch.observer/filing/0001104659-26-019405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.